HitGen Inc. (SHA:688222)

China flag China · Delayed Price · Currency is CNY
22.72
+0.42 (1.88%)
At close: Aug 22, 2025, 2:57 PM CST
1.88%
Market Cap9.08B
Revenue (ttm)426.34M
Net Income (ttm)65.70M
Shares Out399.44M
EPS (ttm)0.17
PE Ratio131.37
Forward PE145.02
Dividend0.06 (0.26%)
Ex-Dividend DateJun 18, 2025
Volume15,570,952
Average Volume24,679,303
Open22.37
Previous Close22.30
Day's Range22.20 - 22.82
52-Week Range8.35 - 26.49
Beta0.23
RSI54.99
Earnings DateAug 28, 2025

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 483
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688222
Full Company Profile

Financial Performance

In 2024, HitGen's revenue was 426.99 million, an increase of 14.99% compared to the previous year's 371.32 million. Earnings were 51.36 million, an increase of 26.13%.

Financial Statements

News

There is no news available yet.